| Kovalyshyn I, Busam KJ, Marghoob AA
Orange-yellow diffuse cutaneous eruption in an 82-year-old woman. [Case Reports, Journal Article]
Arch Dermatol 2009 Oct; 145(10):1183-8.
Full Citation | Publisher Full Text | Find Related Articles |
| Mohty M
Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! [Journal Article]
Leukemia 2009 Oct; 23(10):1689-90.
Full Citation |
| Giannoni A, Aquaro DG, Masi L, et al.
[An atypical case of cardiac amyloidosis] [English Abstract, Journal Article]
Recenti Prog Med 2009 May; 100(5):247-52.
Abstract | Full Citation |
| Goldschmidt H
[Autologous stem cell transplantation in multiple myeloma - pro] [Journal Article]
Dtsch Med Wochenschr 2009 Sep; 134(39):1942.
Full Citation | Publisher Full Text | Find Related Articles |
| Zheng Y, Cai Z, Wang S, et al.
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. [JOURNAL ARTICLE]
Blood 2009 Aug 26.
Abstract | Full Citation | Find Related Articles |
| Bölling T, Dirksen U, Ranft A, et al.
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data. [Journal Article]
Strahlenther Onkol 2009 Aug.:21-2.
Full Citation | Find Related Articles |
| Lashkari A, Chow WA, Valdes F, et al.
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma. [Journal Article]
Anticancer Res 2009 Aug; 29(8):3281-8.
Abstract | Full Citation |
| de Souza JA, Saliba RM, Patah P, et al.
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. [Journal Article]
Biol Blood Marrow Transplant 2009 Sep; 15(9):1094-9.
Abstract | Full Citation |
| Imataki O, Ohnishi H, Ohbayashi Y, et al.
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen. [Journal Article]
Int J Clin Oncol 2009 Jun; 14(3):197-201.
Abstract | Full Citation | Find Related Articles |
| Sportès C, Steinberg SM, Liewehr DJ, et al.
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. [Journal Article]
Biol Blood Marrow Transplant 2009 Aug; 15(8):963-70.
Abstract | Full Citation |
  |
